Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized Phase II Trial by the Cancer and Leukemia Group B (CALGB 19803)

BACKGROUND: The CALGB evaluated oral topotecan administered at two schedules and doses for MDS. METHODS: Patients with previously untreated primary or therapy-related MDS were eligible. Patients with refractory anemia (RA), RA with ringed sideroblasts (RARS), or refractory cytopenia with multilineag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Grinblatt, David L., Yu, Daohai, Hars, Vera, Vardiman, James W., Powell, Bayard L., Nattam, Sreenivasa, Silverman, Lewis R., de Castro, Carlos, Stone, Richard M., Bloomfield, Clara D., Larson, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2887616/
https://ncbi.nlm.nih.gov/pubmed/19025972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23995
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados